Effects of probiotic bacteria, isoflavones and simvastatin on lipid profile and atherosclerosis in cholesterol-fed rabbits: a randomized double-blind study by Cavallini, Daniela CU et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Lipids in Health and Disease
Open Access Research
Effects of probiotic bacteria, isoflavones and simvastatin on lipid 
profile and atherosclerosis in cholesterol-fed rabbits: a randomized 
double-blind study
Daniela CU Cavallini*1, Raquel Bedani1, Laura Q Bomdespacho1, 
Regina C Vendramini2 and Elizeu A Rossi1
Address: 1Department of Food & Nutrition, Faculty of Pharmaceutical Sciences, Sao Paulo State University, Araraquara, SP, Brazil and 2Department 
of Clinical Analysis, Faculty of Pharmaceutical Sciences, Sao Paulo State University, Araraquara, SP, Brazil
Email: Daniela CU Cavallini* - daniducavallini@ig.com.br; Raquel Bedani - raquelbedani@yahoo.com.br; 
Laura Q Bomdespacho - labomespacho@yahoo.com.br; Regina C Vendramini - vendras@fcafr.unesp.br; Elizeu A Rossi - rossiea@fcfar.unesp.br
* Corresponding author    
Abstract
Background: Much attention has been drawn to different alternative strategies for cardiovascular
disease prevention. Objective: The aim of the present study was to observe and compare the
effects of Enterococcus faecium CRL183 (probiotic microorganism), an isoflavones mixture and
simvastatin (drug used to treat hypercholesterolemia) on lipid parameters and atherosclerosis
development in rabbits with induced hypercholesterolemia.
Methods: The animals were randomly allocated to 5 experimental groups (n = 6) for 60 days:
control (C) that did not consume cholesterol, hypercholesterolemic (H) that consumed an
atherogenic diet (1.0% cholesterol wt/wt), hypercholesterolemic plus E. faecium (HE),
hypercholesterolemic plus isoflavone (HI) and hypercholesterolemic plus simvastatin (HS). Total
and HDL-cholesterol and triglycerides were determined by enzymatic methods; non-HDL-C was
calculated by subtracting HDL-C from total cholesterol; and atherosclerosis was presented as the
percentage of lesion area, relative to the total area from the aorta segment analyzed.
Results: Simvastatin significantly reduced the tot cholesterol (16%) and non-HDL-C level (17%)
and increased the HDL-C (98%), compared to group H. E. faecium raised the HDL-C level by 43.3%
(P < 0.05). Isoflavone decreased the total cholesterol and non-HDL-C concentrations (9%), but this
effect was not statistically significant. At the end of the treatments, groups HE and HS had
significantly lower levels of triglycerides in relation to H and HI. The atherosclerotic lesion area in
the aortic arch was not different between groups. The extent of atherosclerosis in the thoracic and
abdominal aorta was reduced in the groups HI and HS by 22.7% and 26.7% respectively, but this
effect was not significant (P > 0.05).
Conclusion: The results indicated that probiotic microorganism E. faecium CRL 183 could be used
to improve the lipid profile as an alternative or an adjuvant for drug therapy. The effectiveness of
simvastatin in the management of blood lipid was confirmed. There wer e  n o  e f f e c t s  o f  s o y
isoflavones, E. faecium and simvastatin on atherosclerosis development.
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Background
Cardiovascular diseases (CVD) are the most common
cause of death around the world. Elevated blood lipid lev-
els are a major determinant of coronary heart disease
(CHD) and others atherosclerotics diseases. Therefore, the
control of hyperlipidemia may lower CVD risk [1,2].
3-Hidroxy 3-metylglutaryl coenzyme A (HMG-CoA)
redutase inhibitors, know also as statins, are considered
the most effective drugs in the management of hypercho-
lesterolemia and prevention of atherosclerosis-related dis-
orders [3,4]. Statins are selective inhibitors of HMG CoA
redutase, the rate-limiting enzyme of cholesterol biosyn-
thesis, reducing low-density lipoprotein (LDL), very low-
density lipoprotein (VLDL) and triglyceride levels [5].
Besides lipid-lowering, statins have additional effects on
atherosclerosis vascular disease, that includes anti-inflam-
matory [6], anti-thrombotic properties [7] and improve of
endothelial function [8].
Currently the high cost of medicines is a limitation for
pharmacological therapy adhesion. Therefore, alternative
strategies for CVD prevention, such as dietary therapy,
have received considerable attention of scientific commu-
nity.
Several studies in animals and humans have shown that
soy and soy isoflavones may protect against CVD through
improves on serum lipid profiles [9,10] and vascular reac-
tivity [11], increases of LDL oxidation resistance [12] and
inhibition thrombus formation [11].
Among the beneficial effects attributed to probiotics and
probiotic-containing food products, the reduction of
blood cholesterol is of particular interest. The primary
probiotic bacteria associated with cholesterol lowering
have been lactobacilli and bifidobacteria, although other
lactic acid bacteria, such as enterococci, are able to pro-
duce this effect [9,13,14].
We demonstrated previously that E. faecium CRL183
reduces cholesterol by 53.85% in an in vitro model [15].
We also showed that a soy product fermented with E. fae-
cium CRL 183 and Lactobacillus helveticus ssp jugurti 416
exhibited a significant hypocholesterolemic effect in ani-
mal tests and clinical trials [16-18]. However the hypoc-
holesterolemic effect of E. faecium CRL 183 strain has not
been studied in vivo model.
Hence, the aim of the present study was to verify and com-
pare the effects of E. faecium CRL183, isoflavones and sim-
vastatin on lipid parameters and atherosclerosis
development in rabbits with induced hypercholestero-
lemia.
Methods
Material
Enterococcus faecium CRL 183 was obtained from Refer-
ence Center for Lactobacilli – CERELA (San Miguel de
Tucumán, Argentina), isoflavone mixture (Isoflavin®:
4.7% genistin, 11.3% genistein, 5.5% daidzin, 17.8%
daidzein, 2.0% glycitin and 1.0% glycitein) were pur-
chased from Galena, (Campinas, SP, Brazil) and simvasta-
tin were purchased from Galena (Campinas, SP, Brazil).
Animals and Diets
The animal experimental protocol received prior approval
from the Research Ethics Committee of the School of
Pharmaceutical Sciences (n° 03/2007 – UNESP at Arar-
aquara, SP, Brazil). New Zealand white male rabbits (n =
30), 8–9 weeks old, weighing 2.5–3.0 Kg, were obtained
from Central Biotery of Sao Paulo State University, Botu-
catu, SP, Brazil. They were housed individually in temper-
ature-controlled rooms (22°C) with a light-dark cycle of
12:12 h. Rabbits were fed a chow diet (Purina, SP, Brazil)
for 1 week to acclimate the animals and then randomly
allocated to 5 experimental groups (n = 6): control (C),
hypercholesterolemic (H), hypercholesterolemic plus E.
faecium (HE), hypercholesterolemic plus isoflavone (HI)
and hypercholesterolemic plus simvastatin (HS). The con-
trol group (C) was fed only with commercial rabbit diet
(Nutri Coelhos Especial Purina), with the following nutri-
tional make-up (per 100 g): 23 g protein, 4 g fats, 49 g car-
bohydrates, 5 g fiber and 10 g minerals. The other groups
(H, HE, HI and HS) were fed on the same rabbit diet, to
which cholesterol (Sigma C 8503) had been added to
induce hypercholesterolemia. The level of cholesterol
added to the diet was adjusted during the protocol (1.0%
to 0.7% after 30 days) to maintain the animal health. To
prepare the supplemented diet, ether-diluted cholesterol
(ethyl ether stabilized with BHT, Carlo Elba, Italy), was
pulverized as a fine mist on to the chow, under a hood,
where it remained for 12 h to allow the solvents to evap-
orate completely. The chow was packed in black plastic
bags and stored -10°C no more than 2 weeks before use.
The rabbits received restrict amounts (125 g/d) of each
diet, because the extent of atherosclerosis depends on
cholesterol intake [19]. The animals had free access to
water during the experimental period. Groups HE, HI and
HS were given, by gavage once a day, E. faecium suspen-
sion (108 CFU), isoflavone (2.1 mg/kg of body weight)
and simvastatin (3.0 mg/kg of body weight), respectively.
To prepare the pure culture of probiotic microorganism,
E. faecium CRL 183 was reinoculated into Tryptic Soy
Broth (Acumedia) and incubated at 37°C for 16 hours.
The cells were centrifuged at 3000 rpm for 5 minutes and
the supernatant discarded. The cells were resuspended in
sterile peptone water and the suspension was stored under
refrigeration until administered to the animals. IsoflavoneLipids in Health and Disease 2009, 8:1 http://www.lipidworld.com/content/8/1/1
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mixture and simvastatin were diluted in sterile water
immediately before use.
All animals were fed experimental diets for 60 days and
were weighed 3 times during the study (0, 30 and 60
days). Food intake was measured daily. Blood were drawn
from the marginal ear veins, after a 14–16-hour fast, at 0,
30 and 60 day of treatment. Samples were centrifuged
(3500 × g for 10 min at 4°C) to separate serum that was
stored (-70°C) until analysis. At the end of 60 d, the rab-
bits were heparinized (Roche, SP, Brazil) and killed by an
overdose of sodium phenobarbital (Cristália, SP, Brazil).
Immediately after the sacrifice the liver, kidneys and heart
were removed and weighed. The role aorta was removed
from its origin (valve aortic) down to the bifurcation of
the internal iliac arteries to analysis of atherosclerotic
lesions.
Determination of the Coefficient of Alimentary Efficacy 
(CAE)
The CEA was defined as the ratio of the difference in body
weight between days 60 and 0 and the amount of food
consumed throughout the experimental period.
Analysis of Serum lipids
The serum levels of TC, HDL-C and triglycerides were
assayed in each rabbit, with the aid of specific enzyme
kits. Total cholesterol was measured by the cholesterol fast
color method [20]. HDL cholesterol was estimated by first
selectively precipitating lipoproteins [21] and then apply-
ing the TC method to the supernatant. Triglycerides were
measured by the triglyceride fast color method [22]. Non-
HDL cholesterol was calculated by subtracting HDL-C
from TC and represented the LDL+IDL+VLDL cholesterol
fractions [23,24].
Analysis of Atherosclerotic Lesions
The aorta was divided into two segments comprising: 1)
arch aortic; 2) thoracic aorta and abdominal aorta. The
material was fixed, overnight at room temperature, in
10% buffered formalin solution and stained with Sudan
IV to visualize areas of atherosclerotic plaque [25]. The
stained aorta was photographed with a digital camera
(Sony) and the sudanophilic lesions were identified and
quantified. The surface area of the atherosclerotic lesions
was measured with an image analyzer system (Imagelab –
USP – Brazil) and expressed as a percentage of the total
surface area covered by lesion, on the arch and thoracic
aorta.
Statistical Analysis
Results are expressed as mean ± standard error of the
mean. The data were tested by analysis of variance
(ANOVA) and the means were compared across groups by
Tukey test, significance being declared when P ≤ 0.05. The
relationship between the percent lesion area and the
blood lipids was determined by linear correlation analy-
sis. All analyses were carried out with the BIOSTAT statis-
tical package.
Results
Food intake, weight gain and organ weight
Daily food intake was higher in the rabbits of C and H
groups. On the other hand, animals that received isofla-
vone and simvastatin showed the lowest food intake, dur-
ing the experiment.
The weight gains of hypercholesterolemic rabbits (group
H) tended to be lower those in the other groups and these
animals exhibited the lower CAE (p < 0.05).
Dietary isoflavones, probiotic bacteria and simvastatin
significantly reduced weights of liver and kidneys com-
pared to group H. Additionally, the rabbits treated with
isoflavones had lower heart weight (Table 1).
Lipid Profiles
Table 2 summarizes the effects of treatments on serum lip-
ids. After 30 days of the study, H group exhibited the high-
est concentration of total cholesterol (TC), not differ
significantly (p < 0.05) of the group HE. The simvastatin
and the isoflavones caused the greatest reductions in TC
Table 1: Effects of E. faecium, isoflavones and simvastatin on food intake, weight gain and organ weight in the rabbits.
G* Food Intake
(g)
Weight gain
(g)
CAE** Liver
(g)
Heart
(g)
Kidney
(g)
C 125.00 ± 0.00a 903.05 ± 124.86a 7.23 ± 0.61a 83.17 ± 3.92c 5.78 ± 0.20b 6.59 ± 0.52b
H 124.93 ± 0.50a 713.40 ± 39.75b 5.71 ± 0.31b 165.90 ± 3.41a 7.06 ± 0.56a 10.02 ± 0.72a
HE 118.17 ± 9.92b 810.57 ± 95.22ab 6.85 ± 0.28a 110.12 ± 7.53b 6.24 ± 0.39ab 7.21 ± 0.46b
HI 110.14 ± 17.52c 851.88 ± 67.04ab 7.76 ± 0.58a 98.22 ± 6.07bc 5.73 ± 0.22b 7.36 ± 0.74b
HS 114.94 ± 13.11bc 796.48 ± 79.76ab 6.93 ± 0.44a 114.73 ± 10.43b 6.17 ± 0.47ab 7.59 ± 0.26b
Values represent mean ± SEM (n = 6).
Statistical comparison of groups: means with identical letters in the same column do not differ significantly (P ≤ 0.05).
*G = Groups: C = control; H = hypercholesterolemic; HE = hypercholesterolemic plus E. faecium; HI = hypercholesterolemic plus isoflavone; HS = 
hypercholesterolemic plus simvastatin.
** Coefficient of Alimentary Efficacy.Lipids in Health and Disease 2009, 8:1 http://www.lipidworld.com/content/8/1/1
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(34.0% and 19.5% respectively), compared to group H. At
the end of the experiment – 30 days after the reduction of
the concentration of cholesterol added to the diet (from
1% to 0.7%) – the groups H, HE and HI showed the high-
est levels of TC without differ among themselves. Simvas-
tatin led to a reduction of 16% for TC compared to the
group that consumed only the feed with the cholesterol
addition (H).
With 30 days of trial, the concentration of HDL-C was
lower (P < 0.05) in animals of the groups H and HI. On
the other hand, animals in groups HS and HE showed lev-
els of HDL-C significantly higher (56.9% and 34.3%,
respectively) to the group H and similar to the control
(C). At the end of the protocol, the simvastatin (HS) was
able to raise the HDL-C by 98.5% and 24.30% compared
to groups H and C, respectively, and this effect was signif-
icantly (P < 0.05) higher than found in other groups. The
rabbits that received the suspension of E. faecium showed
an increase of 43.3% in this cholesterol fraction in rela-
tion of the group H, without differ from the control group
(C). The animals treated with isoflavone exhibited HDL-C
concentration similar to the H and HE groups (p ≤ 0.05).
The fraction nHDL-C exhibited a similar behavior to that
observed for the CT.
The animals of group H presented basal triglycerides level
significantly lower to the other groups (P < 0.05). At the
end of the protocol groups HE and HS had significantly
lower levels of triglycerides (P < 0.05) compared to groups
H and HS.
Extent of Atherosclerosis
None animals on regular diet developed evidence of
atherosclerosis. In contrast, all rabbits on cholesterol-
enriched diet developed atherosclerosis (Figure 1). The
distribution of atherosclerotic lesion over entire aorta was
similar in all groups of hypercholesterolemic animals,
with the aortic arch contributed between 68% and 83%.
The lesion area of the aortic arch did not differ between
groups. The extent of atherosclerosis in the thoracic and
abdominal aorta was reduced in the HI and HS groups by
22.7% and 26.7%, respectively compared to the group H
(no significant P < 0.05). Thoracic and abdominal lesions
area was positively correlated with TC and non-HDL-C
concentrations (Table 3).
Discussion
The cholesterol added to the chow diet induced hypercho-
lesterolemia in groups H relative to control animals and
none of treatments was able to reducing the serum lipids
to basal levels.
After 30 days, the soy isoflavones reduced by 19.5% the
TC and n-HDL-C. However, this effect was not main-
tained until the end of the protocol. Several studies have
evaluated the effect of isoflavones, associated or not with
the soy protein, in lipid levels and the results are not uni-
form. Song et al. (2006) [23] observed in hamsters that
Table 2: Serum lipids among the groups.
Serum lipids Time C H HE HI HS
TC
(mg/dl)
T0 49.0 ± 3.7a 42.0 ± 2.8a 46.3 ± 2.7a 46.0 ± 1.9a 49.0 ± 5.6a
T30 63.3 ± 4.3d 3650.0 ± 138.0a 3413.5 ± 192.7a 2938.5 ± 154.5b 2409.3 ± 154.1c
T60 53.3 ± 6.2c 2556.5 ± 120.3a 2605.0 ± 166.2a 2327.0 ± 130.9ab 2146.0 ± 172.7b
HDL-C
(mg/dl)
T0 31.5 ± 2.3a 28.5 ± 2.5 a 30.3 ± .5 a 29.8 ± 1.9a 32.5 ± 4.8a
T30 38.3 ± 2.1a 25.5 ± 0.9c 34.3 ± 2.7ab 30.8 ± 1.8bc 40.0 ± 3.1a
T60 26.8 ± 2.8b 16.8 ± 2.8d 24.0 ± 1.9bc 20.5 ± 2.1cd 33.3 ± 3.3a
n-HDL-C
(mg/dl)
T0 17.5 ± 2.6a 13.5 ± 2.9a 16.0 ± 2.0a 16.3 ± 1.92a 16.5 ± 1.1a
T30 25.0 ± 2.6d 3624.5 ± 138.0a 3379.3 ± 193.1a 2907.8 ± 154.5b 2369.3 ± 156.8c
T60 26.5 ± 4.4c 2539.8 ± 120.2a 2581.5 ± 166.2a 2307.0 ± 71.3ab 2112.8 ± 183.1b
Triglycerides
(mg/dl)
T0 90.0 ± 5.3a 66.0 ± 7.3b 99.5 ± 9.5a 99.3 ± 9.2a 94.0 ± 4.2a
T30 57.5 ± 2.9d 260.3 ± 9.4a 122.8 ± 20.4c 203.3 ± 3.6b 110.0 ± 4.7c
T60 53.0 ± 4.5c 245.5 ± 25.9a 115.8 ± 6.4b 215.0 ± 7.1a 104.0 ± 17.2b
Values (in mg/dL) represent mean ± SEM (n = 6). Statistical comparison of groups: means with identical minuscules letters in the same line do not 
differ significantly (P ≤ 0.05). C = control; H = hypercholesterolemic; HE = hypercholesterolemic plus E. faecium; HI = hypercholesterolemic plus 
isoflavone; HS = hypercholesterolemic plus simvastatin.Lipids in Health and Disease 2009, 8:1 http://www.lipidworld.com/content/8/1/1
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Percent of aortic area – A = arch segment; B = thoracic segment – covered by lesion Figure 1
Percent of aortic area – A = arch segment; B = thoracic segment – covered by lesion. The bar graphs represent the 
average (n = 6) for each group with standard errors. H = hypercholesterolemic; HE = hypercholesterolemic plus E. faecium; HI 
= hypercholesterolemic plus isoflavone; HS = hypercholesterolemic plus simvastatin.
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soy protein with or without isoflavones and daidzein pro-
duced similar plasma cholesterol-lowering effects. Lee et
al. (2007) [26] demonstrated that glycitein lessened
plasma cholesterol in female hamsters compared with a
casein control diet, an effect not observed with daidzein
and genistein at the same doses.
Previous study showed that the E. faecium CRL 183 was
capable of reducing total cholesterol by 54% in an in vitro
model [15]. However, the results of this work did not con-
firm the effect of pure culture of E. faecium CRL 183 in ani-
mal model. Rossi et al. (1999) [16] developed a soy
yogurt, fermented by Enterococcus faecium CRL 183 (probi-
otic microorganism) and Lactobacillus helveticus ssp jugurti
416. This product exhibited a significant hypocholestero-
lemic effect in clinical trials and animal tests [17,18]. It is
possible that the components of soy yogurt and the bioac-
tive compounds produced during the fermentative proc-
ess have been involved in these lowering-cholesterol
effects.
Statins competitively inhibit HMG-CoA reductase, the
rate-limiting enzyme of the mevalonate pathway, thereby
decreasing intra-cellular cholesterol synthesis. The result-
ing decrease in hepatic intra-cellular cholesterol concen-
tration results in compensatory increase in the expression
of hepatic LDL receptors, which clear LDL from the circu-
lation [5]. In this study the rabbits treated with simvasta-
tin showed a reduction of 16% in cholesterol total and
non-HDL-C levels compared to hypercholesterolemic rab-
bits (group H), though serum cholesterol levels remain
much higher than in normolipidemic animals. Our
results are in agreement with those observed by others
researchers. Al-Zuhair et al. (1997) [27] showed that sim-
vastatin (1.86 mg/Kg, twice daily) produced significant
reductions by 17%, 31.5% and 21% in LDL-C, triglycer-
ides and total cholesterol levels in cholesterol-fed rabbits
(0.5% wt/wt diet). Shiomi et al. (2004) [28] demon-
strated that simvastatin (15 mg/Kg/52 days) reduced the
total cholesterol by about 20%in rabbits.
Probiotic bacteria (E. faecium CRL 183) was able to pre-
vent the reduction of HDL-C compared to control group
and to raise this lipoprotein compared to group H
(43.3%). We demonstrated previously that a soy product
fermented with E. faecium CRL 183 increased by 18% and
10% the concentration of HDL-C of health rabbits and
adults men, respectively [17,18].
Simvastatin promoted an increase of 98.5% in HDL-C
compared to group H. These results are higher than those
recorded in literature, where the administration of statins
results in a modest increase in HDL-C (5% to 10%) [3,4].
In this study, simvastatin and probiotic microorganism
prevented the elevation of triglycerides during the proto-
col. Previous studies showed that soy yogurt fermented
with E. faecium CRL 183 did not alter the triglycerides
level in animals and humans [17,18]. On the other hand,
the HMG-CoA reductase inhibitors have been considered
effective at lowering triglyceride – or more specifically,
VLDL triglyceride – levels [29,30].
The correlation between blood cholesterol and the extent
of atherosclerosis has been well established in human and
animal model [31,32]. We observed a positive correlation
between TC, n-HDL-C and extent of atherosclerosis lesion
in the thoracic-abdominal aorta.
In the present study soy isoflavone and simvastatin
tended to reduce the atherosclerostic lesion in cholesterol-
fed rabbits, but this effect was not significant (P < 0.05).
This data not confirm the earlier findings by others that
isoflavones and simvastatin reduce atherosclerosis devel-
opment in animals. Yamakoshi et al. (2000) [19] reported
that the extent of atherosclerosis in the aortic arch of cho-
lesterol-fed rabbits was significantly reduced in the isofla-
vone groups (26.3% – 36.9%) Fukuo et al (1991) [33]
observed that the extent of atherosclerosis lesions on tho-
racic-abdominal aorta was lower in the simvastatin (10
mg/Kg) treated animals than in the controls, but the dif-
ference was significant only in the young rabbits (3
months). Differences on experimental design could be
responsible to the observed results in this study.
The potential effects of isoflavones on CDV protection
include modulation of pro-inflammatory cytokines; cell
adhesion proteins and NO formation; protection of LDL
against oxidation; inhibition of platelet aggregation and
improvement in vascular reactivity [9-11]. The discovery
of statins led to important improvements in prevention of
CDV diseases. Recent data suggest that apart their lipid-
lowering effects, statins have a range of anti-inflammatory
and anti-thrombotic properties and seem to improve
endothelial function [5]. Additional studies are necessary
to confirm the effect of isoflavone and simvastatin on
atherosclerosis development.
Conclusion
In conclusion, the results indicated that the probiotic
microorganism  E. faecium CRL 183 could be used to
Table 3: Correlations of serum lipids and atherosclerotic lesions
Serum Lipids Pearson Correlation Coefficients (r)
Aortic Arch Thoracic Aorta
Total Cholesterol -0.08 0.99
HDL-C -0.49 -0.52
nHDL-C 0.24 0.92
Triglycerides 0.32 0.19Lipids in Health and Disease 2009, 8:1 http://www.lipidworld.com/content/8/1/1
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improve lipid profile as an alternative or an adjuvant for
drug therapy. Simvastatin confirmed its effectiveness in
the management of blood lipid. There were no significant
effects of soy isoflavones, E. faecium and simvastatin on
atherosclerosis development.
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